Drug interaction between clopidogrel and proton pump inhibitors

Cardiology in Review

Volumn 17, Issue 4, 2009, Pages 198-200

  Khalique, Saira Chand ^a   Cheng Lai, Angela ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse outcomes; Clopidogrel; Interaction; Plavix; PPI; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; CLOPIDOGREL; CYTOCHROME P450; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; TACROLIMUS; THEOPHYLLINE; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; AREA UNDER THE CURVE; BLEEDING TENDENCY; CLINICAL TRIAL; CORONARY STENT; DIGESTIVE SYSTEM ULCER; DRUG FATALITY; DRUG INHIBITION; DRUG METABOLISM; DRUG RECEPTOR BINDING; HEART DISEASE; HEART REINFARCTION; HUMAN; IN VIVO STUDY; LOADING DRUG DOSE; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 68049115736     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181a857ba     Document Type: Review

References (22)

1. Gilard M, Arnaud B, Cornily J, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
2. Ho M, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
3. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118: 1894-1909.
4. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-718.
5. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetic and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475-484.
6. Farid NA, Payne CD, Small D, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;8:735-741.
7. [No authors listed]. PPI interactions with clopidogrel revisited. Med Lett Drug Ther. 2009;51:13-14.
8. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157: 148.e1-148.e5.
9. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13:27-36.
10. Anderson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole, and pantoprazole. Clin Pharmacokinet. 1996;31:9-28.
11. Meyer UA. Metabolic interactions of lansoprazole, omeprazole, and pantoprazole with other drugs. Eur J Gastroenterol Hepatol. 1996;8(suppl 1):S21-S25.
12. Li X, Andersson T, Alstrom M, et al. Comparison of the inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome p450 activities. Drug Metab Dispos. 2004;32:821-827.
13. Vandenbranden M, Ring B, Binkley S, et al. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics. 1196;39:511-518.
14. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991;20:38-49.
15. Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990;47:79-85.
16. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987;24:543-545.
17. Lefebrve R, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther. 1992; 52:458-463.
18. Blue H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety. 2006;29:769-784.
19. Scheiman JM. Strategies to reduce the GI risks of antiplatelet therapy. Rev Cardiovasc Med. 2005;6(suppl 4):S23-S31.
20. Liberopoulos EN, Elisaf MS, Tselepis AD, et al. Upper gastrointestinal hemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets. 2006;17:1-6.
21. Ng FH, Wong SY, Lam KF, et al. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol. 2008;103:865-871.
22. Food and Drug Administration. "Early Communication about an Ongoing Safety Review of clopidogrel bisulfate." January 26, 2009. Available at: http://www.fda.gov/Cder/drug/early-comm/clopidogrel-bisulfate.htm. Accessed March 5, 2009.